Plain-English translation of NCT06449677 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing the iLet Bionic Pancreas System, a device that automatically delivers insulin to help manage blood sugar in people with cystic fibrosis-related diabetes. Half of the participants will use the new device for 13 weeks while continuing their regular blood sugar monitoring, and the other half will use their usual insulin delivery method. After 13 weeks, everyone will have the chance to use the bionic pancreas for another 13 weeks.
People with cystic fibrosis-related diabetes struggle to manage their blood sugar because of the unique challenges their disease creates. This trial is testing whether an automated insulin delivery system can help keep blood sugar more stable and reduce the burden of managing insulin manually.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either start using the bionic pancreas right away or continue with your usual insulin method for the first 13 weeks. Either way, you'll wear a continuous glucose monitor to track your blood sugar. You'll have regular study visits to check how well the treatment is working and ensure it's safe. After 13 weeks, if you weren't using the bionic pancreas initially, you'll get to start using it for the final 13 weeks of the study.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States